𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Association of anemia and cognitive dysfunction in patients with acute myelogenous leukemia and myelodysplastic syndrome

✍ Scribed by Susan M. Wood; Christina A. Meyers; Stefan Faderl; Hagop M. Kantarjian; Sherry A. Pierce; Guillermo Garcia-Manero

Publisher
John Wiley and Sons
Year
2011
Tongue
English
Weight
324 KB
Volume
86
Category
Article
ISSN
0361-8609

No coin nor oath required. For personal study only.

πŸ“œ SIMILAR VOLUMES

Possible association between Budd-Chiari
Possible association between Budd-Chiari syndrome and gemtuzumab ozogamicin treatment in a patient with refractory acute myelogenous leukemia
✍ MevlΓΌt Kurt; Ali Shorbagi; Kadri Altundag; Tamer Elkiran; Ibrahim GΓΌllΓΌ; Emin Ka πŸ“‚ Article πŸ“… 2005 πŸ› John Wiley and Sons 🌐 English βš– 86 KB πŸ‘ 1 views

## Abstract Gemtuzumab ozogamicin (GO; CMA‐676; Mylotargβ„’) is a chemotherapeutic agent approved for the treatment of CD33‐positive acute myelogenous leukemia in patients of age 60 years or older after first relapse. Hepatic veno‐occlusive disease has been reported to develop as a late complication

Effect of androgen therapy and anemia on
Effect of androgen therapy and anemia on serum erythropoietin levels in patients with aplastic anemia and myelodysplastic syndromes
✍ Piedras, Josefa; HernΓ‘ndez, Guadalupe; LΓ³pez-Karpovitch, Xavier πŸ“‚ Article πŸ“… 1998 πŸ› John Wiley and Sons 🌐 English βš– 53 KB πŸ‘ 2 views

Immunoreactive serum erythropoietin (EPO) was measured in anemic and non-anemic patients with acquired non-severe aplastic anemia (AA; n = 22) and myelodysplastic syndromes (MDS; n = 31) receiving or not androgens to examine the effect of androgen therapy and anemia on EPO levels in these disorders.